Skandinaviska Enskilda Banken AB publ Reduces Stake in Roivant Sciences Ltd. (NASDAQ:ROIV)

Skandinaviska Enskilda Banken AB publ lessened its stake in shares of Roivant Sciences Ltd. (NASDAQ:ROIV) by 42.1% during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The firm owned 115,476 shares of the company’s stock after selling 83,811 shares during the period. Skandinaviska Enskilda Banken AB publ’s holdings in Roivant Sciences were worth $1,318,000 as of its most recent filing with the Securities & Exchange Commission.

Several other institutional investors and hedge funds have also recently modified their holdings of the company. Nordea Investment Management AB raised its stake in Roivant Sciences by 22.5% during the fourth quarter. Nordea Investment Management AB now owns 282,834 shares of the company’s stock worth $3,306,000 after purchasing an additional 52,031 shares during the period. TOMS Capital Investment Management LP acquired a new stake in shares of Roivant Sciences during the 3rd quarter worth approximately $46,333,000. Barclays PLC increased its holdings in shares of Roivant Sciences by 19.7% during the 3rd quarter. Barclays PLC now owns 459,521 shares of the company’s stock worth $5,302,000 after buying an additional 75,609 shares during the last quarter. Loomis Sayles & Co. L P raised its position in shares of Roivant Sciences by 13.3% during the 3rd quarter. Loomis Sayles & Co. L P now owns 3,912,205 shares of the company’s stock valued at $45,147,000 after buying an additional 458,601 shares during the period. Finally, Retirement Systems of Alabama lifted its holdings in Roivant Sciences by 26.9% in the third quarter. Retirement Systems of Alabama now owns 530,022 shares of the company’s stock valued at $6,116,000 after acquiring an additional 112,286 shares during the last quarter. Institutional investors and hedge funds own 64.76% of the company’s stock.

Insider Transactions at Roivant Sciences

In other news, COO Eric Venker sold 100,000 shares of the business’s stock in a transaction dated Friday, December 20th. The stock was sold at an average price of $11.49, for a total value of $1,149,000.00. Following the completion of the sale, the chief operating officer now directly owns 595,580 shares of the company’s stock, valued at approximately $6,843,214.20. The trade was a 14.38 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, CIO Mayukh Sukhatme sold 185,946 shares of the firm’s stock in a transaction that occurred on Tuesday, December 24th. The stock was sold at an average price of $12.00, for a total value of $2,231,352.00. Following the transaction, the executive now owns 18,836,547 shares in the company, valued at $226,038,564. This represents a 0.98 % decrease in their position. The disclosure for this sale can be found here. In the last quarter, insiders sold 2,388,170 shares of company stock worth $27,612,299. 7.90% of the stock is currently owned by insiders.

Roivant Sciences Price Performance

Roivant Sciences stock opened at $10.85 on Tuesday. The stock has a market cap of $7.74 billion, a PE ratio of -72.33 and a beta of 1.26. The stock’s fifty day moving average is $10.80 and its two-hundred day moving average is $11.49. Roivant Sciences Ltd. has a 1-year low of $9.76 and a 1-year high of $13.06.

Roivant Sciences (NASDAQ:ROIV) last issued its earnings results on Monday, February 10th. The company reported ($0.20) earnings per share for the quarter, topping the consensus estimate of ($0.24) by $0.04. Roivant Sciences had a negative return on equity of 14.05% and a negative net margin of 119.54%. On average, research analysts expect that Roivant Sciences Ltd. will post -0.92 earnings per share for the current fiscal year.

Analyst Ratings Changes

ROIV has been the topic of several research analyst reports. Cantor Fitzgerald upgraded shares of Roivant Sciences to a “strong-buy” rating in a report on Tuesday, March 4th. HC Wainwright restated a “buy” rating and set a $18.00 target price on shares of Roivant Sciences in a report on Tuesday, February 11th. One equities research analyst has rated the stock with a hold rating, five have issued a buy rating and one has issued a strong buy rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Buy” and a consensus price target of $18.08.

Roivant Sciences Company Profile

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups.